EPA and DHA as markers of nutraceutical treatment response in major depressive disorder.

Adult Biomarkers / analysis Depressive Disorder, Major / diet therapy Dietary Supplements Docosahexaenoic Acids / analysis Double-Blind Method Eicosapentaenoic Acid / analysis Erythrocyte Membrane / chemistry Female Humans Male
Biomarker Depression Nutraceutical Omega-3 Precision medicine

Journal

European journal of nutrition
ISSN: 1436-6215
Titre abrégé: Eur J Nutr
Pays: Germany
ID NLM: 100888704

Informations de publication

Date de publication:
Sep 2020
Historique:
received: 27 03 2019
accepted: 06 09 2019
pubmed: 27 9 2019
medline: 26 5 2021
entrez: 27 9 2019
Statut: ppublish

Résumé

Depression clinical trials are increasingly studying biomarkers to predict and monitor response to treatment. Assessment of biomarkers may reveal subsets of patients who are responsive to nutraceutical treatment, which may facilitate a personalized approach to treating depression. This is a post hoc analysis of an 8-week, double-blind, randomized, controlled trial (n = 158) investigating a combination nutraceutical comprising Omega-3 (EPA 1 g/DHA 656 mg), SAMe, zinc, 5-HTP, folinic acid, and co-factors versus placebo for the treatment of Major Depressive Disorder. The study explored levels of polyunsaturated fatty acids, folate, vitamin B12, zinc, homocysteine, and BDNF as possible predictors and correlates of response to nutraceutical supplementation. Concentrations of EPA and DHA in red cell membranes increased in response to treatment and were significantly correlated with a decrease in depressive symptoms during active treatment (p = 0.003 and p = 0.029; respectively). Higher baseline levels of omega-6 fatty acid also correlated with depression reduction in the active treatment group ( p = 0.011). No other biomarkers were associated with a lessening of depressive symptoms. Changes in fatty acid levels resulting from a nutraceutical combination containing EPA and DHA provide a response biomarker in treating depression.

Identifiants

DOI: 10.1007/s00394-019-02090-6 PMID: 31555976
pubmed: 31555976
doi: 10.1007/s00394-019-02090-6
pii: 10.1007/s00394-019-02090-6
doi:

Substances chimiques

Biomarkers 0
Docosahexaenoic Acids 25167-62-8
Eicosapentaenoic Acid AAN7QOV9EA

Types de publication

Clinical Trial, Phase II Clinical Trial, Phase III Journal Article Multicenter Study Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

2439-2447

Subventions

Organisme : National Health and Medical Research Council
ID : APP1048222

Références

Rush AJ (2007) Limitations in efficacy of antidepressant monotherapy. J Clin Psychiatry 68(Suppl 1):8–10
pubmed: 17900203
Sarris J, Logan AC, Akbaraly TN et al (2015) Nutritional medicine as mainstream in psychiatry. Lancet Psychiatry 2:271–274. https://doi.org/10.1016/S2215-0366(14)00051-0
doi: 10.1016/S2215-0366(14)00051-0 pubmed: 26359904
Sarris J, Murphy J, Mischoulon D, et al (2016) Adjunctive nutraceuticals for depression: a systematic review and meta-analyses. Am J Psychiatry appiajp201615091228. https://doi.org/10.1176/appi.ajp.2016.15091228
Raison CL, Rutherford RE, Woolwine BJ et al (2013) A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. Arch Gen Psychiatry. https://doi.org/10.1001/2013.jamapsychiatry.4
doi: 10.1001/2013.jamapsychiatry.4
Rao TSS, Asha MR, Ramesh BN, Rao KSJ (2008) Understanding nutrition, depression and mental illnesses. Indian J Psychiatry 50:77–82. https://doi.org/10.4103/0019-5545.42391
doi: 10.4103/0019-5545.42391 pubmed: 19742217 pmcid: 2738337
Venigalla H, Mekala HM, Hassan M et al (2017) An update on biomarkers in psychiatric disorders—are we aware, do we use in our clinical practice? Ment Health Fam Med 13:471–479
Sarris J, Byrne GJ, Stough C et al (2019) Nutraceuticals for major depressive disorder—more is not merrier: an 8-week double-blind, randomised, controlled trial. J Affect Disord 245:1007–1015. https://doi.org/10.1016/J.JAD.2018.11.092
doi: 10.1016/J.JAD.2018.11.092 pubmed: 30699842
Sarris J, Stough C, Bousman C et al (2015) An adjunctive antidepressant nutraceutical combination in treating major depression: study protocol, and clinical considerations. Adv Integr Med 2:49–55. https://doi.org/10.1016/j.aimed.2015.02.001
doi: 10.1016/j.aimed.2015.02.001
Rapaport MH, Nierenberg AA, Schettler PJ et al (2015) Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study. Mol Psychiatry. https://doi.org/10.1038/mp.2015.22
doi: 10.1038/mp.2015.22 pubmed: 25802980
Carney RM, Steinmeyer BC, Freedland KE et al (2016) Baseline blood levels of omega-3 and depression remission: a secondary analysis of data from a placebo-controlled trial of omega-3 supplements. J Clin Psychiatry. https://doi.org/10.4088/JCP.14m09660
doi: 10.4088/JCP.14m09660 pubmed: 26930527 pmcid: 5369023
Mazereeuw G, Herrmann N, Andreazza AC et al (2017) Oxidative stress predicts depressive symptom changes with omega-3 fatty acid treatment in coronary artery disease patients. Brain Behav Immun. https://doi.org/10.1016/j.bbi.2016.10.005
doi: 10.1016/j.bbi.2016.10.005 pubmed: 27742581
Freeman MP, Hibbeln JR, Silver M et al (2011) Omega-3 fatty acids for major depressive disorder associated with the menopausal transition: a preliminary open trial. Menopause. https://doi.org/10.1097/gme.0b013e3181f2ea2e
doi: 10.1097/gme.0b013e3181f2ea2e pubmed: 21738078 pmcid: 3158958
Ganança L, Galfalvy HC, Oquendo MA et al (2017) Lipid correlates of antidepressant response to omega-3 polyunsaturated fatty acid supplementation: a pilot study. Prostaglandins Leukot Essent Fat Acids. https://doi.org/10.1016/j.plefa.2017.03.004
doi: 10.1016/j.plefa.2017.03.004
Martins JG (2009) Epa but not dha appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials. J Am Coll Nutr. https://doi.org/10.1080/07315724.2009.10719785
doi: 10.1080/07315724.2009.10719785 pubmed: 20439549
Lin P-Y, Huang S-Y, Su K-P (2010) A meta-analytic review of polyunsaturated fatty acid compositions in patients with depression. Biol Psychiatry 68:140–147. https://doi.org/10.1016/j.biopsych.2010.03.018
doi: 10.1016/j.biopsych.2010.03.018 pubmed: 20452573
Lai J, Moxey A, Nowak G et al (2012) The efficacy of zinc supplementation in depression: systematic review of randomised controlled trials. J Affect Disord 136:e31–e39. https://doi.org/10.1016/j.jad.2011.06.022
doi: 10.1016/j.jad.2011.06.022 pubmed: 21798601
Firth J, Teasdale SB, Allott K et al (2019) The efficacy and safety of nutrient supplements in the treatment of mental disorders: a meta-review of meta-analyses of randomized controlled trials. World Psychiatry 18(3):308–324
doi: 10.1002/wps.20672
Syed EU (2013) Vitamin B12 supplementation in treating major depressive disorder: a randomized controlled trial. Open Neurol J. https://doi.org/10.2174/1874205x01307010044
doi: 10.2174/1874205x01307010044 pubmed: 24339839 pmcid: 3856388
Desseilles M, Witte J, Chang TE et al (2013) Massachusetts general hospital SAFER criteria for clinical trials and research. Harv Rev Psychiatry 21:269–274. https://doi.org/10.1097/HRP.0b013e3182a75cc7
doi: 10.1097/HRP.0b013e3182a75cc7 pubmed: 24651559
Zhou C, Zhong J, Zou B et al (2017) Meta-analyses of comparative efficacy of antidepressant medications on peripheral BDNF concentration in patients with depression. PLoS One. https://doi.org/10.1371/journal.pone.0172270
doi: 10.1371/journal.pone.0172270 pubmed: 29281694 pmcid: 5744959
Wickham H (2009) Ggplot2: elegant graphics for data analysis. Springer, Berlin
doi: 10.1007/978-0-387-98141-3
van der Burg KP, Cribb L, Firth J, Karmacoska D, Sarris J (2019) Nutrient and genetic biomarkers of nutraceutical treatment response in mood and psychotic disorders: a systematic review. Nutr Neurosci. https://doi.org/10.1080/1028415X.2019.1625222
doi: 10.1080/1028415X.2019.1625222 pubmed: 31397223
Carney RM, Freedland KE, Rubin EH et al (2009) Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease: a randomized controlled trial. JAMA. https://doi.org/10.1001/jama.2009.1487
doi: 10.1001/jama.2009.1487 pubmed: 19843899
Grosso G, Galvano F, Marventano S, Malaguarnera M, Bucolo C, Drago F, Caraci F (2014) Omega-3 fatty acids and depression: Scientific evidence and biological mechanisms. Oxid Med Cell Longev. 2014:313570. https://doi.org/10.1155/2014/313570
doi: 10.1155/2014/313570 pubmed: 24757497
Moylan S, Berk M, Dean OM et al (2014) Oxidative & nitrosative stress in depression: why so much stress?. Neurosci Biobehav, Rev
Raison CL, Capuron L, Miller AH (2006) Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 27:24–31
doi: 10.1016/j.it.2005.11.006
Stark KD, Van Elswyk ME, Higgins MR et al (2016) Global survey of the omega-3 fatty acids, docosahexaenoic acid and eicosapentaenoic acid in the blood stream of healthy adults. Prog, Lipid Res
doi: 10.1016/j.plipres.2016.05.001
Lin PY, Huang SY, Su KP (2010) A meta-analytic review of polyunsaturated fatty acid compositions in patients with depression. Biol Psychiatry. https://doi.org/10.1016/j.biopsych.2010.03.018
doi: 10.1016/j.biopsych.2010.03.018 pubmed: 20691429
Sarris J, Murphy J, Mischoulon D et al (2016) Adjunctive nutrient nutraceuticals for depression: a systematic review and meta-analyses. Am J Psychiatry 173:575–587
doi: 10.1176/appi.ajp.2016.15091228
Brown RD, Langshaw MR, Uhr EJ et al (2011) The impact of mandatory fortification of flour with folic acid on the blood folate levels of an Australian population. Med J Aust 194:65–67
doi: 10.5694/j.1326-5377.2011.tb04169.x
Polyakova M, Stuke K, Schuemberg K et al (2015) BDNF as a biomarker for successful treatment of mood disorders: a systematic & quantitative meta-analysis. J Affect, Disord
McIntyre RS, Subramaniapillai M, Lee Y et al (2019) Efficacy of adjunctive infliximab vs placebo in the treatment of adults with bipolar I/II depression: a randomized clinical trial. JAMA Psychiatry. https://doi.org/10.1001/jamapsychiatry.2019.0779
doi: 10.1001/jamapsychiatry.2019.0779 pubmed: 31066887 pmcid: 6506894
Lapillonne A, DeMar JC, Nannegari V, Heird WC (2002) The fatty acid profile of buccal cheek cell phospholipids is a noninvasive marker of long-chain polyunsaturated fatty acid status in piglets. J Nutr 132:2319–2323
doi: 10.1093/jn/132.8.2319
Lopresti AL, Maker GL, Hood SD, Drummond PD (2014) A review of peripheral biomarkers in major depression: the potential of inflammatory and oxidative stress biomarkers. Prog Neuro-Psychopharmacol Biol Psychiatry 48:102–111
doi: 10.1016/j.pnpbp.2013.09.017
Miller AH, Raison CL (2016) The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol 16:22
doi: 10.1038/nri.2015.5

Auteurs

Kiki P van der Burg (KP)

MaSc Medicine at University Medical Center Utrecht (UMCU), Utrecht, The Netherlands.

Lachlan Cribb (L)

Professorial Unit, The Melbourne Clinic, Department of Psychiatry, The University of Melbourne, Melbourne, Australia.

Joseph Firth (J)

NICM Health Research Institute, Western Sydney University, Westmead, Australia.
Division of Psychology and Mental Health, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.

Diana Karmacoska (D)

NICM Health Research Institute, Western Sydney University, Westmead, Australia.

David Mischoulon (D)

Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Gerard J Byrne (GJ)

Faculty of Medicine, Discipline of Psychiatry, Centre for Clinical Research, Royal Brisbane and Women's Hospital, The University of Queensland, Herston, Australia.

Chad Bousman (C)

Departments of Medical Genetics, Psychiatry, and Physiology and Pharmacology, University of Calgary, Calgary, AB, Canada.
Department of Psychiatry, The University of Melbourne, Melbourne, Australia.

Con Stough (C)

Centre for Human Psychopharmacology, Swinburne University of Technology, Hawthorn, Australia.

Jenifer Murphy (J)

Professorial Unit, The Melbourne Clinic, Department of Psychiatry, The University of Melbourne, Melbourne, Australia.

Georgina Oliver (G)

Professorial Unit, The Melbourne Clinic, Department of Psychiatry, The University of Melbourne, Melbourne, Australia.

Michael Berk (M)

Department of Psychiatry, The University of Melbourne, Melbourne, Australia.
IMPACT SRC, Barwon Health, School of Medicine, Deakin University, Geelong, Australia.
Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Australia.
Orygen, The Centre of Excellence in Youth Mental Health, The University of Melbourne, Parkville, Australia.

Chee H Ng (CH)

Professorial Unit, The Melbourne Clinic, Department of Psychiatry, The University of Melbourne, Melbourne, Australia.

Jerome Sarris (J)

Professorial Unit, The Melbourne Clinic, Department of Psychiatry, The University of Melbourne, Melbourne, Australia. j.sarris@westernsydney.edu.au.
NICM Health Research Institute, Western Sydney University, Westmead, Australia. j.sarris@westernsydney.edu.au.
ORCID: 0000-0001-9287-8854

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › EPA and DHA as markers of nutraceutical...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › EPA and DHA as markers of nutraceutical...
questionsmedicales.fr › Troubles mentaux › Troubles de l'humeur › Trouble dépressif › Trouble dépressif majeur › EPA and DHA as markers of nutraceutical...
questionsmedicales.fr › Aliments et boissons › Aliments › Compléments alimentaires › EPA and DHA as markers of nutraceutical...
questionsmedicales.fr › Lipides › Huiles › Huiles de poisson › Acides gras omega-3 › Acide docosahexaénoïque › EPA and DHA as markers of nutraceutical...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Méthodologie en recherche épidémiologique › Méthode en double aveugle › EPA and DHA as markers of nutraceutical...
questionsmedicales.fr › Lipides › Huiles › Huiles de poisson › Acides gras omega-3 › Acide eicosapentanoïque › EPA and DHA as markers of nutraceutical...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Sang › Cellules sanguines › Érythrocytes › Membrane érythrocytaire › EPA and DHA as markers of nutraceutical...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › EPA and DHA as markers of nutraceutical...